Business Wire (Thu, 8:30AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,668 people get ACTC.OB articles and Market Currents by email alert.
Get email alerts on ACTC.OB »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (May 9, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Apr 16, 2013)
-
Business Wire (Apr 15, 2013)
-
Business Wire (Mar 12, 2013)
-
Earnings Preview: Pluristem TherapeuticsVytautas Drumelis • Tue, Jun 19, 2012
-
Business Wire (Thu, 8:30AM)
-
Business Wire (May 9, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Apr 16, 2013)
-
Business Wire (Apr 15, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Mar 8, 2013)
-
Business Wire (Mar 7, 2013)
-
Business Wire (Mar 4, 2013)
ACTC.OB vs. ETF Alternatives
Company Description
Currently, there's no company description for ACTC.OB.
-
- View all 3 replies
-
rseiter: This one is called a buy and forget ...it either stays at 8 cents forever, goes to zero or explodes one day when you re not looking -
Noreika: Good point. I need to stop checking every hour before I go crazy. I have my core position, now I need to stop obsessing.
-
- View all 16 replies
-
John Motyka: Funk: I subscribe to zmescience. It is Free and most interesting. Lots of breaking news on cutting edge of science projects worldwide...jdm -
-
- View all 6 replies
-
John Motyka: Michael: Go to singularityhub.com for free newsletter. Rich source of stem cell news including recent Lancet article plus many others...jdm -
-
- View all 4 replies
-
Funkengruven: I meant to say "hoping" as opposed to "guessing", cuz I believe that is a possibility gbstern. -
jalphabet: They knew market manipulation would bring it back down along with dilution so sold to reinvest/buyback shares when it really counts. #ACTC
-
John Motyka
What cratered ACTC.OB? Lancet has most promising article about their small trials using donated stem cells. RSVP invited...JDM - View all 11 replies
-
John Motyka: Hey Funk~ You should add ALU to that lineup of 'Sleepers'. All worthy, but still not on fire. The sharks will come around to them too...JDM -
Funkengruven: Thanks JDM.... Got a small position, thinking about adding if it dips.
-
- View all 5 replies
-
Funkengruven: I'll take good news re 2 patients over nothing... had the stock too long and need something! -
LATEST REPLIES
-
- View all 3 replies
-
rseiter: This one is called a buy and forget ...it either stays at 8 cents forever, goes to zero or explodes one day when you re not looking -
Noreika: Good point. I need to stop checking every hour before I go crazy. I have my core position, now I need to stop obsessing.
-
- View all 16 replies
-
John Motyka: Funk: I subscribe to zmescience. It is Free and most interesting. Lots of breaking news on cutting edge of science projects worldwide...jdm -
-
- View all 6 replies
-
John Motyka: Michael: Go to singularityhub.com for free newsletter. Rich source of stem cell news including recent Lancet article plus many others...jdm -
-
John Motyka
What cratered ACTC.OB? Lancet has most promising article about their small trials using donated stem cells. RSVP invited...JDM - View all 11 replies
-
John Motyka: Hey Funk~ You should add ALU to that lineup of 'Sleepers'. All worthy, but still not on fire. The sharks will come around to them too...JDM -
Funkengruven: Thanks JDM.... Got a small position, thinking about adding if it dips.
-
- View all 4 replies
-
Funkengruven: I meant to say "hoping" as opposed to "guessing", cuz I believe that is a possibility gbstern. -
jalphabet: They knew market manipulation would bring it back down along with dilution so sold to reinvest/buyback shares when it really counts. #ACTC
-
- View all 5 replies
-
Funkengruven: I'll take good news re 2 patients over nothing... had the stock too long and need something! -
-
Iosonorico
BioTime, Inc. (BTIM-RETIRED) uses ACTC.OB technology to support their R&D efforts (pay attention to page 46) http://bit.ly/7A286 - View all 1 replies
-
-
- View all 3 replies
-
jalphabet: my guess is that something good is imminently going to come from that phase 1/2 stem cell trial. Or, these are leftovers from Geron. -
-
jalphabet
Leading Eye Institute to Participate in ACTC.OB Embryonic Stem Cell Clinical Trial for Macular Degeneration http://yhoo.it/x6ddrV - View all 1 replies
-
Pancho1901: Just more good news. Reading between the lines, the human trials are working!!
-
- View all 4 replies
-
-
jalphabet: thank you very much for this. its exciting to find other people so excited about this stock